Cargando…
Outcome of ALL With ALL-BFM-95 Protocol in Nepal
PURPOSE: Data on survival outcomes in patients with acute lymphoblastic leukemia (ALL) originating from Nepal are limited. We aim to present the real-world data on treatment outcomes of patients with de novo ALL treated with pediatric ALL-Berlin-Frankfurt-Muenster (BFM)-95 protocol in Nepal. PATIENT...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581644/ https://www.ncbi.nlm.nih.gov/pubmed/37428991 http://dx.doi.org/10.1200/GO.22.00408 |
_version_ | 1785122180127784960 |
---|---|
author | Sharma Poudyal, Bishesh Paudel, Bishal Tuladhar, Sampurna Neupane, Samir Bhattarai, Kushal Joshi, Utsav |
author_facet | Sharma Poudyal, Bishesh Paudel, Bishal Tuladhar, Sampurna Neupane, Samir Bhattarai, Kushal Joshi, Utsav |
author_sort | Sharma Poudyal, Bishesh |
collection | PubMed |
description | PURPOSE: Data on survival outcomes in patients with acute lymphoblastic leukemia (ALL) originating from Nepal are limited. We aim to present the real-world data on treatment outcomes of patients with de novo ALL treated with pediatric ALL-Berlin-Frankfurt-Muenster (BFM)-95 protocol in Nepal. PATIENTS AND METHODS: We used the medical records of 103 consecutive patients with ALL treated in our center from 2013 to 2016 to evaluate the overall survival (OS) and relapse-free survival (RFS) and analyzed the effects of clinicopathologic factors on survival outcomes in patients with ALL. RESULTS: The 3-year OS and RFS in the entire cohort was 89.4% (95% CI, 82.1 to 96.7) and 87.3% (95% CI, 79.8 to 94.7), with a mean OS and RFS of 79.4 months (95% CI, 74.2 to 84.5) and 76.6 months (95% CI, 70.8 to 82.4), respectively. Patients with prednisone good response (PGR) showed better mean OS and RFS, whereas complete marrow response on day 33 was associated with better mean OS alone. Patients with Philadelphia (Ph)-positive ALL showed worse mean RFS compared to those with Ph-negative status. On multivariate analysis, PGR (hazard ratio [HR], 0.11; 95% CI, 0.03 to 0.49; P = .004) and sagittal vein thrombosis (SVT; HR, 5.95; 95% CI, 1.30 to 27.18; P = .02) were the only independent predictors of OS and RFS, respectively. Adverse events on BFM-95 protocol included SVT (4.9%), peripheral neuropathy (7.8%), myopathy (20.4%), hyperglycemia (24.3%), intestinal obstruction (7.8%), avascular necrosis of femur (6.8%), and mucositis (46%). CONCLUSION: BFM-95 protocol appears to be a safe and effective strategy in adolescent and young adults and adult Nepalese population with ALL with a low toxicity profile. |
format | Online Article Text |
id | pubmed-10581644 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-105816442023-10-18 Outcome of ALL With ALL-BFM-95 Protocol in Nepal Sharma Poudyal, Bishesh Paudel, Bishal Tuladhar, Sampurna Neupane, Samir Bhattarai, Kushal Joshi, Utsav JCO Glob Oncol SPECIAL ARTICLES PURPOSE: Data on survival outcomes in patients with acute lymphoblastic leukemia (ALL) originating from Nepal are limited. We aim to present the real-world data on treatment outcomes of patients with de novo ALL treated with pediatric ALL-Berlin-Frankfurt-Muenster (BFM)-95 protocol in Nepal. PATIENTS AND METHODS: We used the medical records of 103 consecutive patients with ALL treated in our center from 2013 to 2016 to evaluate the overall survival (OS) and relapse-free survival (RFS) and analyzed the effects of clinicopathologic factors on survival outcomes in patients with ALL. RESULTS: The 3-year OS and RFS in the entire cohort was 89.4% (95% CI, 82.1 to 96.7) and 87.3% (95% CI, 79.8 to 94.7), with a mean OS and RFS of 79.4 months (95% CI, 74.2 to 84.5) and 76.6 months (95% CI, 70.8 to 82.4), respectively. Patients with prednisone good response (PGR) showed better mean OS and RFS, whereas complete marrow response on day 33 was associated with better mean OS alone. Patients with Philadelphia (Ph)-positive ALL showed worse mean RFS compared to those with Ph-negative status. On multivariate analysis, PGR (hazard ratio [HR], 0.11; 95% CI, 0.03 to 0.49; P = .004) and sagittal vein thrombosis (SVT; HR, 5.95; 95% CI, 1.30 to 27.18; P = .02) were the only independent predictors of OS and RFS, respectively. Adverse events on BFM-95 protocol included SVT (4.9%), peripheral neuropathy (7.8%), myopathy (20.4%), hyperglycemia (24.3%), intestinal obstruction (7.8%), avascular necrosis of femur (6.8%), and mucositis (46%). CONCLUSION: BFM-95 protocol appears to be a safe and effective strategy in adolescent and young adults and adult Nepalese population with ALL with a low toxicity profile. Wolters Kluwer Health 2023-07-10 /pmc/articles/PMC10581644/ /pubmed/37428991 http://dx.doi.org/10.1200/GO.22.00408 Text en © 2023 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/ |
spellingShingle | SPECIAL ARTICLES Sharma Poudyal, Bishesh Paudel, Bishal Tuladhar, Sampurna Neupane, Samir Bhattarai, Kushal Joshi, Utsav Outcome of ALL With ALL-BFM-95 Protocol in Nepal |
title | Outcome of ALL With ALL-BFM-95 Protocol in Nepal |
title_full | Outcome of ALL With ALL-BFM-95 Protocol in Nepal |
title_fullStr | Outcome of ALL With ALL-BFM-95 Protocol in Nepal |
title_full_unstemmed | Outcome of ALL With ALL-BFM-95 Protocol in Nepal |
title_short | Outcome of ALL With ALL-BFM-95 Protocol in Nepal |
title_sort | outcome of all with all-bfm-95 protocol in nepal |
topic | SPECIAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581644/ https://www.ncbi.nlm.nih.gov/pubmed/37428991 http://dx.doi.org/10.1200/GO.22.00408 |
work_keys_str_mv | AT sharmapoudyalbishesh outcomeofallwithallbfm95protocolinnepal AT paudelbishal outcomeofallwithallbfm95protocolinnepal AT tuladharsampurna outcomeofallwithallbfm95protocolinnepal AT neupanesamir outcomeofallwithallbfm95protocolinnepal AT bhattaraikushal outcomeofallwithallbfm95protocolinnepal AT joshiutsav outcomeofallwithallbfm95protocolinnepal |